Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
bioMD Limited (ASX: BOD) today announced a change of corporate name to reflect the merger with Allied Medical Ltd earlier this month. The new Company will be called Allied Healthcare Group Ltd and trade under the ASX code AHZ.
New research from the Royal College of Surgeons in Ireland (RCSI) has identified a novel drug target for the treatment of infection in bone.
For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients. Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.
A new technique for producing artificial bone implants has been developed by Korean researchers. Published in the journal Science and Technology of Advanced Material (STAM), the technique combines two methods to approximate both types of bone tissue. By mimicking natural bone, it is hoped the implant material will better complement the natural regeneration process.
BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced that it has become the leading supplier of pre-formulated GMP cryopreservation media for umbilical cord blood stem cells, a key segment of the Company's strategic biobanking market.
Joseph M. Lane, M.D., an orthopedic surgeon nationally recognized for his work in metabolic bone disease, will receive the Lifetime Achievement Award at the hospital's 28th Annual Tribute Dinner on Monday, June 20, for his innovative research on bone disease and the use of bisphosphonates in treating osteoporosis. Brian Williams, anchor of Nightly News on NBC, will serve as toastmaster.
bioMD Limited (ASX:BOD), a company with assets in regenerative tissue engineering technologies today announced the appointment of a new Chairman, a new MD and other changes to its Board. This follows shareholder approval for the acquisition of Allied Medical Ltd., a company that specialises in the sales, distribution and commercialisation of medical technologies.
Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.
Medical scientists now have "clear" evidence that the damaged cartilage tissue in osteoarthritis and other painful joint disorders can be encouraged to regrow and regenerate, and are developing tissue engineering technology that could help millions of patients with those disorders.
Manufacturers temperature controlled microscopy, Linkam Scientific Instruments, have been chosen by the Physics Department of the University of Liverpool to study the effects of controlling stresses applied during the growth of collagen secreted from human fibroblast cells. The research goal of Senior Research Assistant, Dr Caroline Smith, and her colleagues at the University of Liverpool is to advance the treatment of tendon injuries by developing a method of growing oriented human collagen.
On June 9-10, Stevens Institute of Technology will host the Stevens Conference on Bacteria-Material Interactions, an event that covers the latest multi-disciplinary research in the area of infection-resistant biomaterials.
A new biomaterial designed for repairing damaged human tissue doesn't wrinkle up when it is stretched. The invention from nanoengineers at the University of California, San Diego marks a significant breakthrough in tissue engineering because it more closely mimics the properties of native human tissue.
PolyPid, a developer of innovative drug carriers, announced today the company’s flagship platform – PolyPid. PolyPid is a new, innovative family of drug carriers, based on a fusion between two known drug delivery systems: polymers and lipid-based systems.
The new drug carriers enable long-lasting and controlled release of therapeutic drugs. The revolutionary, patented carrier can be tailored to almost any drug – small molecules, peptides, protein and nucleic acids-based drugs. The formulations can be pre-planned in order to achieve the desired release rate of the drug/s and the optimal duration, which can last up to several months.
Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.
Victims of third-degree burns and other traumatic injuries endure pain, disfigurement, invasive surgeries and a long time waiting for skin to grow back. Improved tissue grafts designed by Cornell scientists that promote vascular growth could hasten healing, encourage healthy skin to invade the wounded area and reduce the need for surgeries.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like’ and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.
In a medical breakthrough, researchers have been able to convert skin cells into liver cells. This could one day eliminate the need for organ transplants, they say.
Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body.
Researchers at Columbia Engineering have established a new method to patch a damaged heart using a tissue-engineering platform that enables heart tissue to repair itself.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.